These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37087525)

  • 1. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
    Li R; Takeda K; Rong A
    Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
    Takeda K; Yamaguchi Y; Taguri M; Morita S
    Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction of Oncology Dose-Finding Trial Designs].
    Takeda K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
    Xia Q; Takeda K; Yamaguchi Y; Zhang J
    Pharm Stat; 2024; 23(4):480-494. PubMed ID: 38295856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
    Takeda K; Zhu J; Li R; Yamaguchi Y
    Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
    Takeda K; Komatsu K; Morita S
    Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
    Kakizume T; Takeda K; Taguri M; Morita S
    Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
    Pan H; Xie F; Liu P; Xia J; Ji Y
    Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C; Bardet A; Geoerger B; Paoletti X
    Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
    Phillips A; Mondal S
    Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.